Compare MIRM & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | GATX |
|---|---|---|
| Founded | 2018 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.2B |
| IPO Year | 2019 | 1994 |
| Metric | MIRM | GATX |
|---|---|---|
| Price | $89.49 | $183.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | $112.00 | ★ $215.00 |
| AVG Volume (30 Days) | ★ 601.2K | 185.1K |
| Earning Date | 05-18-2026 | 05-22-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | ★ 74.59 | 17.22 |
| EPS | N/A | ★ 9.12 |
| Revenue | $19,138,000.00 | ★ $1,740,400,000.00 |
| Revenue This Year | $24.61 | $39.80 |
| Revenue Next Year | $21.75 | $3.49 |
| P/E Ratio | ★ N/A | $20.21 |
| Revenue Growth | N/A | ★ 9.77 |
| 52 Week Low | $36.88 | $139.44 |
| 52 Week High | $109.28 | $199.00 |
| Indicator | MIRM | GATX |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 46.39 |
| Support Level | $72.17 | $179.71 |
| Resistance Level | $107.51 | $186.61 |
| Average True Range (ATR) | 3.75 | 5.26 |
| MACD | -2.53 | -1.53 |
| Stochastic Oscillator | 12.45 | 20.72 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.